Efficacy of Different Durations of Intravenous Methylprednisolone Treatment in Relapses of Multiple Sclerosis

Kulu U., Tiftikcioglu B. I., Zorlu Y., Cetiner M., Sener U., Tuna G., ...Daha Fazla

NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, cilt.54, sa.1, ss.57-61, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 54 Sayı: 1
  • Basım Tarihi: 2017
  • Doi Numarası: 10.5152/npa.2016.12382
  • Dergi Adı: NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.57-61
  • Anahtar Kelimeler: Interleukin-10, intravenous methylprednisolone, glucocorticoids, relapsing-remitting multiple sclerosis, treatment duration, INTERLEUKIN-12, CYTOKINES, GLUCOCORTICOIDS, THERAPY, CELLS, IL-12, MS
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Introduction: Relapses of multiple sclerosis (MS) are usually treated with high-dose intravenous methylprednisolone (IVMP), given over 3-10 days. There is no consensus on the optimal duration of treatment. In this study, we aimed to investigate whether longer treatment provides additional short-term clinical benefits assessed by the change in plasma cytokine levels and EDSS scores in patients with relapsing-remitting MS (RRMS).